



Understanding the impact of cancer diagnosis and treatment on everyday life

6 MONTH BREAST CANCER CRF

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copy of the baseline CRF when completing this 6 month CRF: the questions marked with a RED ASTERISK need only be answered if they were marked "not currently known", "unknown" or left blank at baseline
- If you have any queries, please contact the HORIZONS Coordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

Participant's Study ID	/	/		

r									
Participant's date of birth	d	d	m	m	У	У	У	У	

Participant's tumour type (please tick one box below, OR tick to indicate the question was answered at baseline)*

This question was answered at baseline

Туре	Sub-type	
Breast	Invasive ductal breast cancer	
	Invasive lobular breast cancer	
	Other (please describe below)	
	Not currently known	

Date of participant's current cancer diagnosis (please add details OR tick to indicate the question was answered at baseline)*

This question was answered at baseline						
Date of current cancer diagnosis						
(date that histological diagnosis was reported)	d d	m m	Y	/ У	У	У

Participant's tumour TNM (Tumour-Node-Metastasis) stage at diagnosis (please add details OR tick to indicate the question was answered at baseline)*

This question was answered at baseline

T_____ N_____ M_____

If TNM is unknown, please complete number staging details overleaf

/	/		

Participant's tumour number stage at diagnosis (please tick one box OR tick to indicate the question was answered at baseline)*

This question was answered at baseline

Stage 1		
Stage 2	Stage 2A	
	Stage 2B	
Stage 3	Stage 3A	
	Stage 3B	
	Stage 3C	

IMPORTANT—YOU SHOULD HAVE ENTERED A TNM OR NUMBER STAGE FOR EACH PARTICIPANT, EITHER IN THIS CRF OR IN THE BASELINE CRF

Participant's tumour grade (please tick one box OR tick to indicate the question was answered at baseline)*

This question was answered at baseline

Grade 1/low grade/well differentiated	
Grade 2/moderate/intermediate grade	
Grade 3/high-grade/poorly differentiated	
Grade not currently known	



Is the participant ER, PR or HER2 positive? (please tick three boxes)

	Positive	Negative	Unknown
ER			
PR			
HER2			

Has the participant been tested for BRCA1 or BRCA2 (please tick one box)*

Yes (already recorded in baseline CRF)	
Yes (but not recorded in baseline CRF)	
No	
Unknown	

If you answered "Yes (but not recorded in baseline CRF)" to the above question, was the result (please tick one box)

Positive for a mutation in BRCA1 or BRCA2	
Negative for a mutation in BRCA1 or BRCA2	
Ambiguous or uncertain	
Unknown	
Awaiting result	

HORIZONS Pilot; 6 month Case Report Form; Breast. Version 2.2, 19/09/2017, IRAS Project ID: 202342, REC reference number 16/NW/0425

Has the participant had any other genetic tests for inherited cancers? (please tick one box)

Yes (already recorded in baseline CRF)	
Yes (but not recorded in baseline CRF)	
No	
Unknown	

If you answered "Yes (but not recorded in baseline CRF)" to the above question, please provide some information about the participant's other genetic test(s) by completing the table(s) below

Name of genetic test for cancer (1)	Result of genetic test
	Positive
	Negative
	Ambiguous/uncertain
	Awaiting result
	Unknown

Name of genetic test for cancer (2)	Result of genetic test
	Positive
	Negative
	Ambiguous/uncertain
	Awaiting result
	Unknown

HORIZONS Pilot; 6 month Case Report Form; Breast. Version 2.2, 19/09/2017, IRAS Project ID: 202342, REC reference number 16/NW/0425

Participant's Study ID	
------------------------	--

Has the participant developed any NEW co-morbidities (which were not recorded in the baseline CRF)? (please tick all that apply)

Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other	
chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	
Clinical diagnosis of depression	
Other psychiatric diagnosis (eg. schizophrenia, bipolar disorder etc.)	



Participant's NEW co-morbidities continued (please tick all that apply)

Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, poly- myositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Morbid Obesity	
Other (please give details)	

Is the participant pre or post menopause? (please tick one box)

Pre menopause	
Post menopause	
Unknown	

Participant's Study ID

dy ID / / /

What was the participant's route to diagnosis (the route they took through the healthcare system before receiving a cancer diagnosis)? (please tick one box)

The participant was diagnosed:	
1. Following attendance at a screening programme (via the national screen- ing programmes for bowel, breast and cervical cancers)	
2. During/following a hospital outpatient appointment which resulted from:	
i) An urgent GP referral for suspected cancer ("Two-week wait")	
ii) A routine GP referral (for symptoms which don't arouse suspicion of can- cer but need investigating)	
iii) A referral from a different outpatient specialty (eg. ENT)	
3. During/following an admission to hospital which was:	
i) An inpatient elective	
ii) An emergency (after an emergency GP referral, during an A&E visit, whilst in hospital due to an emergency)	
4. Other (please give details)	
5. Unknown	

Participant's Study ID



What treatments has the participant received, please tick ALL that apply and write details in the spaces provided

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason why
Surgery	Wide local excision (breast conserving surgery)		// 20		
	Mastectomy		// 20		
	Sentinel node biopsy (SNBx)		//20		
	Axiliary node clearance (ANC)		// 20		
	Other axiliary treatment please describe on line below)		// 20		
Breast recon- struction	Immediate reconstruction		// 20		
	Delayed reconstruction		//20		
	Delayed reconstruction is planned but has not yet taken place				
Reconstruction type	Implant				
	Latissimus dorsi (LAD)				
	Deep inferior epigastric perforator artery (DIEP)				
	Tissue reconstruction with abdominal tissue (TRAM)				
	Nipple reconstruction				
	Other (please describe on line below)				

HORIZONS Pilot; 6 month Case Report Form; Breast. Version 2.2, 19/09/2017, IRAS Project ID: 202342, REC reference number 16/NW/0425

Participant's Study ID	/	/		
raiticipant s Study iD	/	/		

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why	
Radiotherapy	Breast		// 20	//20		
	Chest wall		//20	/ / 20		
	Supraclavicular fossa (SCF)		// 20	// 20		
	Axilla		//20	/ / 20		
	Number of radiotherapy fra	actions, ple	ase enter on line			
	Total radiotherapy dose ple	ease enter	on line			
Neo-adjuvant chemotherapy	Drug(s), please give details below		//20	//20		
	Neo-adjuvant chemotherapy number of cycles, please enter on line					
Chemotherapy	Drug(s), please give details below		//20	//20		
	Chemotherapy number of o	cycles, plea	se enter on line			

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Hormone	Tamoxifen		// 20	// 20	
therapy					
	Anastrazole		// 20	/ / 20	
	Letrozole		// 20	// 20	
	Exemestane		/ / 20	// 20	
	Other, please give details below		//20	// 20	
	Was hormone therapy give Yes No Unknow		rian suppression (pl	ease tick)	
	Was hormone therapy give Yes No Unknov		phosphonates (pleas	se tick)	
Symmeterisation operations	Contralateral prophylactic mastectomy		//20	// 20	
	Other symmeterisation operation (please give details)		//20	//20	
Immunotherapy	Trastuzumab (Herceptin)		//20	// 20	
	Pertuzumab (Perjeta)		//20	// 20	
	Other immunotherapy (please give details		// 20	//20	

Participant's Study ID
Is the participant taking part in a clinical trial? (please tick one box)
Yes No Unknown
If you answered "yes" to the above question, please give the NAME of the clini- cal trial the participant is taking part in
Name of clinical trial
Since the participant's diagnosis of breast cancer, have they been diagnosed with an- other new primary cancer? (please tick one box)

Yes No Unknown


If you answered "yes" to the above question, please provide some information about the participant's new cancer diagnosis by completing the table below

Details of participant's new cancer diagnosis

Type of cancer	
Date of diagnosis	//20
Treatment received	
Date treatment ended (if finished)	//20

Participant's Study ID
Has the participant had a recurrence of their breast cancer? (please tick one box)
Yes No
If the participant has had a recurrence, on what date was the recurrence
diagnosed?
If the participant has had a recurrence, was the recurrence local or distant? (please tick one box)
Local recurrence
Distant recurrence
If the participant has had a recurrence, is any further treatment planned? (please
tick one box and if "yes" give details) Yes No
Please describe any planned treatment
What type of follow-up care is the participant receiving? (please tick ONE box)
Routine/regular hospital clinic based follow-up (medical or nurse led, face-
to-face or by telephone)
Primary care based follow-up
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)
If the participant is receiving patient-initiated follow-up, on what date were
they discharged to this?

Participant's Study ID



1

|/| |

Holistic Needs Assessment? (please tick all that apply)

Participant has been referred to palliative care services	
Participant has been referred to psychological services	
Participant has been referred to community services	
Participant has had an HNA (holistic needs assessment)	

If the participant has died please give the date and cause of death:

Participant's date of death

	-						_
d d		m	m	У	У	У	У

Cause of participant's death

1) a)	
1) b)	
1) c)	
2)	

Cause of death not known

Please add your name and signature and the date that you completed this CRF

Name	Signature
Date CRF completed	d d / m m / y y y